SCHEMBL6985429

SCHEMBL6985429

NC(=O)c1cnc2c([N+](=O)[O-])cccc2c1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.54
MEN1 O00255 6/20 0.54
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 5/20 0.54
TDP1 Q9NUW8 4/20 0.54
MAPT P10636 5/20 0.43
LMNA P02545 2/20 0.43
SLC2A1 P11166 1/20 0.43
HAVCR2 Q8TDQ0 1/20 0.42
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MITF O75030 1/20 0.41
PDE10A Q9Y233 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
NOS1 P29475 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537393 0.86 MEN1 (0.54) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL4785490 0.80 KMT2A (0.64) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL6537368 0.79 ALDH1A1 (0.67) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL7622343 0.78 SLC2A1 (0.50) KMT2AMEN1KDM4ESLC2A1HAVCR2
SCHEMBL28489879 0.78 HAVCR2 (0.44) KMT2AMEN1ALDH1A1KDM4ESLC2A1
SCHEMBL6537643 0.77 MEN1 (0.59) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL6537483 0.77 ALDH1A1 (0.59) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL308476 0.76 TSHR (0.49) KMT2AMEN1ALDH1A1TDP1LMNA
SCHEMBL7803244 0.75 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL7793503 0.75 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KMT2A 1250/4885MEN1 2187/4885ALDH1A1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.